POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
68 hedge funds and large institutions have $318M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 9 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
167% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 9
64% more capital invested
Capital invested by funds: $194M → $318M (+$124M)
24% more funds holding
Funds holding: 55 → 68 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$5.04M |
| 4 |
Millennium Management
New York
|
+$3.58M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.86M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$4.33M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.32M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$343K |
| 5 |
Goldman Sachs
New York
|
-$288K |
PNT Hedge Fund Activity: Q1 2022 in Review
68 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q1 2022, worth a combined $318M — up 64% from $194M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PNT positions and 6 closed out — a net gain of 13 holders — while 24 added to existing stakes and 9 trimmed.
The largest buyer was Great Point Partners, adding an estimated $11.9M. The largest seller was Farallon Capital Management, cutting an estimated $6.86M.
- 68 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q1 2022, up from 55 in Q4 2021.
- Funds reported $318M of POINT Biopharma Global Inc. Common Stock stock for Q1 2022, up 64% quarter-over-quarter.
- 19 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q1 2022 and 6 closed out, a net change of +13 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q1 2022 was Great Point Partners, an estimated $11.9M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q1 2022 was Farallon Capital Management, an estimated $6.86M sold.
Based on aggregated 13F filings for Q1 2022.